Mazdutide — Benefits, Dosage & Where to Buy
Research Overview
Mazdutide is a dual GLP-1/glucagon receptor agonist co-developed by Eli Lilly and Innovent Biologics, primarily targeting the Chinese and global obesity markets. Like survodutide, it combines appetite suppression from GLP-1 receptor agonism with increased energy expenditure from glucagon receptor activation. In phase 2 trials, mazdutide demonstrated dose-dependent weight loss of up to 11.7% at 24 weeks, with improvements in glycemic control, lipid profiles, and blood pressure. The compound is further along in development in China, where it received breakthrough therapy designation. Phase 3 trials are ongoing in both Chinese and global populations.
Key Research Findings
- •Dual GLP-1/glucagon receptor agonist
- •Up to 11.7% weight loss in 24-week phase 2 trial
- •Once-weekly subcutaneous injection
- •Improvements in HbA1c, lipids, and blood pressure
- •Breakthrough therapy designation in China
- •Phase 3 trials ongoing globally
Published Research (1 studies)
- [1]
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (2 products from 2 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Skye Peptides | $99.00 $16.50/mg 6mg lyophilized | Out |
| Polaris Peptides | $100.00 $16.67/mg 6mg lyophilized | Out |